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Abstract: Respiratory disease has never received priority in relation to its impact on health. 
Estimated DALYs lost in 2002 were 12% globally (similar for industrialized and developing 
countries). Chronic airﬂ  ow limitation (due mainly to asthma and COPD) alone affects more 
than 100 million persons in the world and the majority of them live in developing countries. 
International guidelines for management of asthma (GINA) and COPD (GOLD) have been 
adopted and their cost-effectiveness demonstrated in industrialized countries. As resources 
are scarce in developing countries, adaptation of these guidelines using only essential drugs is 
required. It remains for governments to set priorities. To make these choices, a set of criteria have 
been proposed. It is vital that the results of scientiﬁ  c investigations are presented in these terms to 
facilitate their use by decision-makers. To respond to this emerging public health problem in devel-
oping countries, WHO has developed 2 initiatives: “Practical Approach to Lung Health (PAL)” and 
the Global Alliance Against Chronic Respiratory Diseases (GARD)”, and the International Union 
Against Tuberculosis and Lung Diseases (The Union) has launched a new initiative to increase af-
fordability of essential asthma drugs for patients in developing countries termed the “Asthma Drug 
Facility” (ADF), which could facilitate the care of patients living in these parts of the world.
Keywords: air ﬂ  ow limitation, asthma, COPD, intervention, cost-effectiveness, developing 
countries;
Introduction 
Chronic respiratory diseases have never, in any area of the world, been accorded a 
priority relative to their extent and impact. No political jurisdiction (rich or poor) 
proportionally commits resources to chronic respiratory diseases equivalent to the 
burden they represent in the community, whether for research, prevention, or clinical 
services. It was only in 2005, that the World Health Organisation (WHO) released 
a report highlighting the high burden of chronic diseases particularly in developing 
countries and the need for urgent action in the prevention and control of chronic diseases 
including chronic respiratory diseases (WHO 2005). The reasons for this neglect are 
unclear. Several possible explanations can be offered. 
These diseases have traditionally been stigmatized. It has been virtually impossible 
to mobilize either patients or society to address them as has been done for HIV/AIDS 
(Mawar et al 2006; Vanable et al 2006), cardiovascular diseases, or cancer (Chapple 
et al 2004). With conditions related to tobacco smoke exposure (lung cancer and 
chronic obstructive pulmonary disease) there has been a ‘blame the victim’ approach 
which promotes stigmatization (Bayer and Stuber 2006). In addition, the main burden 
of conditions such as tuberculosis and pneumonia in children are highly associated 
with poverty and inequity which in turn is fraught with a sense of ‘powerlessness’ 
which mitigates against social mobilization (Anyangwe et al 2006). 
Unlike cancer or cardiovascular diseases, the various respiratory conditions have 
been ‘partitioned’ to other ‘categories’ (even though they are generally managed International Journal of COPD 2007:2(2)  142
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within a single subspecialty of medicine) and are thus not 
‘counted’ as a single entity, to be compared with other groups. 
Examples include lung cancer (counted as ‘cancer’), acute 
respiratory illnesses (especially pneumonia), and tubercu-
losis (often managed by lung specialists but ‘counted’ with 
infectious diseases). 
Finally, these diseases (and especially chronic airﬂ  ow 
limitation) can be ‘silent’. Even where there is extensive 
knowledge and expertise concerning them, they are fre-
quently unrecognized. For example, if one reviews the 
medical records of a sample of patients on an adult medical 
ward in industrialized countries, the frequency with which 
chronic airﬂ  ow limitation is mentioned in the clinical record 
is usually much less than the prevalence of the disease 
in the community; the frequency of the condition among 
hospitalized patients in a medical ward is most certainly 
substantially higher.
This article seeks to address the issue of chronic airﬂ  ow 
limitation; a major contributor to the burden of chronic 
respiratory disease. It will focus on the situation in developing 
countries where the majority of the world’s population lives. 
It will outline what is known about the burden of disease 
and  available interventions and will propose an approach 
to setting priority for action. For the purposes of this article, 
chronic airﬂ  ow limitation refers to diseases that cause re-
duced pulmonary function related to disease of the airways 
and includes both ﬁ  xed airﬂ  ow limitation (as in chronic 
obstructive pulmonary disease (COPD), bronchiectasis, and 
the sequelae of tuberculosis) and variable airﬂ  ow limitation 
(as in asthma).
Burden of disease
Calculation of the burden of all respiratory diseases combined 
can be made from recent published reports (Lopez et al 2006) 
and indicates that respiratory diseases account for 15% of 
deaths in low-middle-income countries and 14% in high-
income countries, second only to cardiovascular diseases 
which account for 21% and 27% respectively. Viewed in 
terms of premature deaths (years of life lost), this is even 
more dramatic: respiratory diseases account for 17%, com-
pared with 15% for other communicable diseases and 14% 
for cardiovascular diseases. Among the respiratory diseases, 
lower respiratory tract infections account for the greatest 
proportion of years of life lost (48% of those due to respira-
tory diseases) with chronic airﬂ  ow limitation accounting for 
a lower proportion (17%).
As part of an effort to prioritize health needs by quantify-
ing the global burden of disease, health economists working 
in conjunction with the World Bank developed “Disability-
Adjusted Life Years” (DALYs); a statistical measurement 
for account for both death and disability (World Bank 1993). 
From the World Health Report 2004 (WHO 2004), the 
estimated DALYs lost due to all respiratory diseases in 2002 
was 184 million (12% of the total) compared with 21% for 
other infectious and parasitic diseases, 13% for neuropsychi-
atric diseases, and 10% for cardiovascular diseases. Among 
the respiratory diseases, lower respiratory tract infections 
accounted for the greatest proportion (50%), with chronic 
airﬂ  ow limitation accounting for 23%.
The prevalence of chronic airﬂ  ow limitation is relatively 
high. The prevalence of asthma in adults (Table 1) has been 
demonstrated between 1% and 10% with a median estimate 
around 2%–3% (ECRHS 1996). Among these cases, it is 
likely that a minority (less than 30%) have chronic airﬂ  ow 
limitation (Aït-Khaled and Enarson 2005), yielding a com-
munity prevalence of asthma with chronic airﬂ  ow limitation 
of 0.5 to 1.0%. The World Health Report 2004 estimates a 
range of COPD up to 1.7%, with the global median at just 
over 1.0%. These are in contrast to prevalence studies of 
COPD in the general population (conﬁ  rmed by spirometry) 
among adults (Table 2) in Europe, America, and Latin 
America (Mueller et al 1971; Gulsvik 1979; Lange et al 
1989; Bakke et al 1991; Marco-Jordan et al 1998; Mannino et 
al 2000; Viegi et al 2000; Von Hertzen et al 2000; Menezes 
et al 2005), where the prevalence varied from 4% to 27%.
The PLATINO study (Menezes et al 2005) describes the 
epidemiology of COPD in ﬁ  ve major Latin American cities: 
Sao Paulo (Brazil), Santiago (Chile), Mexico City (Mexico), 
Table 1 Estimated prevalence of asthma symptoms
 Region  Estimated  prevalence
Children 13–14 years * 
 Oceania  25.9%
 North  America  16.5%
 Latin  America  13.4%
 Western  Europe  13.0%
 Eastern  Mediterranean  10.7%
 Africa  10.4%
 Paciﬁ  c Asia  9.4%
 South-East  Asia    4.5%
 Eastern  Europe  4.4%
Adults aged 20–44 years ** 
  Australia and New Zealand  6.8–9.7%
  USA and Northen Europe  >5.0%
  Western Europe and Mediterranean  1.0–4.0%
 Alger  (Algeria)  2.4%
 Bombay  (India)  2.6%
Note: * The International Study of Asthma and Allergies in Childhood (ISAAC); 
**The European Community Respiratory Health Survey (ECRHS)International Journal of COPD 2007:2(2)  143
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Montevideo (Uruguay), and Caracas (Venezuela). The same 
methodology was used and COPD deﬁ  ned as a ratio less than 
0.7 of postbronchodilator forced expiratory volume in the 
ﬁ  rst second (FEV1) divided by forced vital capacity (FVC). 
Crude rates of COPD ranged from 7.8% (95% CI 5.9–9.7) in 
Mexico City to 19.7% (95% CI 17.2–22.2) in Montevideo. 
After adjustment for key risk factors, the prevalence of 
COPD in Mexico City remained signiﬁ  cantly lower than that 
in other cities. Altitude may explain part of the difference 
in prevalence. These results suggest that COPD is a greater 
health problem in Latin America than previously realised 
and suggests of a high prevalence of COPD in developing 
countries and particularly in middle income countries which 
are in similar epidemiologic transition (North and South 
Africa, Asia). 
The ﬁ  gures are based on very limited information. There 
are virtually no community-based surveys of the prevalence 
of chronic airﬂ  ow limitation in low-income countries (such 
as the countries of Africa). More extensive information is 
available for asthma where the International Study of Asthma 
and Allergy in Childhood (ISAAC) has led the way in pro-
viding comparative results from across the world (Beasley 
et al 1998). However, this initiative providing a worldwide 
map of prevalence of asthma symptoms (Table 1) has not 
yet provided results of lung function and is thus not able to 
give estimates of chronic airﬂ  ow limitation among asthma 
patients. Moreover, its focus is children, which means that 
population estimates will under represent the situation. 
More recent initiatives, such as the Burden of Obstructive 
Lung Disease (BOLD) study, will hopefully improve our 
knowledge, however this very costly survey will be difﬁ  cult 
to conduct in low and in the majority of middle countries. It 
is lamentable that information on a condition as widespread 
and as devastating as chronic airﬂ  ow limitation is so lack-
ing and underscores the point that these patients are greatly 
underserved. 
Based on the available data, the combined community 
prevalence of airﬂ  ow limitation due to the two conditions 
could be estimated in excess of 100 million persons (possibly 
substantially higher). Estimated DALYs lost in 2002 can be 
compared among regions (WHO 2004). For comparative pur-
poses and to illustrate the situation in low-income countries, 
those for Africa can be compared with the global estimates. 
DALYs lost due to all respiratory diseases were 14% for 
Africa compared with 12% globally. Among the respiratory 
diseases, lower respiratory tract infections accounted for 
a much greater proportion in Africa (68% compared with 
50%), COPD accounted for just over 2% compared with 15% 
and asthma for just over 4% compared with 8% globally. 
Among patients seeking care in the health services of various 
developing countries implementing the “Practical Approach 
to Lung Health” asthma and COPD represent more than 1% 
of all consultations (Table 3).
These estimates, however, must be viewed with extreme 
caution due to the severe limitation in data upon which they 
are based and the prevalence of chronic airﬂ  ow limitation 
may be substantially higher than currently believed (as was 
the case in the studies in Latin America by Menezes and 
colleagues [2005]). Nevertheless, even with the limited in-
formation available, we must conclude that chronic airﬂ  ow 
limitation does account for a substantial  burden of disease, 
even in the poorest countries where life expectancy is drasti-
cally lower and the effects of such chronic diseases would be 
expected to be consequently less. That so little attention is 
Table 2 Prevalence in general population of airway obstruction  by spirometry (FEV1/FVC <70%)
Regions  Countries  Year  Age group  Prevalence of air way obstruction  (%)  Authors
      Overall  Male    Females 
Europe  Danemark   1989  20–90  3.7      Lange  
 Finland    2000  ≥30   11  5.2  Von  Hertzen
 Italy    2000  ≥25 11  12.5  11.8  Viegy 
 Norway  1979  16–69  4.1  3.7  4.6  Gulsvik 
   1991  18–70  4.5  4.8  4.2  Bakke 
 Spain  2000  40–69  9.1  14.3  3.9  Maro-Jordan
America USA  1971  20–69    13  2  Mueller
   2000  ≥17 6.8      Mannino
Latin America  Brazil (Sao Paulo)  2002  >40    18  14  Menezes
 Chili  (Santiago)       23.3  12.8   
 Mexico         11  5.5   
 Uruguay  (Montevideo)       27.1  14.5   
 Venezuela  (Caracas)       15.7  10.2
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity. International Journal of COPD 2007:2(2)  144
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given to respiratory diseases in general, and to chronic airﬂ  ow 
limitation in particular, in this setting is a travesty. 
The ﬁ  nancial consequences of chronic respiratory dis-
eases are high and underscore the need for more investment 
on research and policy. The cost of asthma has increased in 
recent years in industrialised countries. For example, in 1998, 
asthma in USA (Weiss and Sullivan 2001) accounted for an 
estimated US$12.7 billions annually (more than 2 times the 
estimated cost for 1990). Data on the direct (cost of health- 
care resources) and indirect (cost of the consequences of 
the disability) costs of COPD are also available only from 
industrialised countries. For example in 1993, the total an-
nual economic burden of COPD in USA was estimated at 
US$23.9 billions (NHLB 1998).These data demonstrate that 
the total cost for COPD is greater than for other common 
respiratory disease such as asthma, inﬂ  uenza, pneumonia 
and tuberculosis. 
Tobacco is the main etiological agent for chronic airﬂ  ow 
limitation worldwide, although exposure to combustion prod-
ucts of biomass fuel is an important and underestimated risk 
factor in developing countries (Baris and Ezzati 2004). 
Interventions to improve prevention 
and management
During the last two decades, guidelines for standard case 
management of asthma and COPD have been adopted in 
most industrialized countries. They began with the Global 
Initiative of Asthma (GINA) (GINA 1995), updated in 
2005. These guidelines recommend standardised manage-
ment for asthma attacks and emphasize the crucial need of 
long-term treatment of asthma to alleviate disease severity, 
improve quality of life and to prevent exacerbations and 
attacks. Prevention aims to limit environmental factors 
that act as triggering factors (essentially allergens and 
tobacco). The technical measures proposed are based on 
the pathophysiology of asthma as a chronic inﬂ  ammatory 
disorder of the airways (explaining the need of regular 
use of inhaled steroids) that lead to recurrent episodes of 
symptoms linked to airﬂ  ow obstruction (explaining the 
need of bronchodilators). The characteristic variability of 
airﬂ  ow limitation in asthma highlights the importance of 
tools to measure and monitor lung function (spirometers and 
peak expiratory ﬂ  ow meters) to conﬁ  rm the diagnosis and 
document the grade of severity. The following principles 
of GINA have been adopted in national guidelines, with 
regional or local adaptations: 
1.  Clear objectives for case management; 
2.  Diagnosis based on clinical history and lung function; 
3. Classiﬁ  cation of severity based on history and lung 
function; 
4.  Long-term treatment adapted to the severity grade; 
5.  Patient education and strong partnership with care pro-
viders to improve adherence to treatment and to promote 
self-management;
6.  Routine follow-up for evaluation and adaptation of treat-
ment.
Following a similar framework, the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD), elaborated 
guidelines for case management, and prevention of COPD 
(GOLD 1998), updated in 2005. They have been adopted by 
most professional societies. The recommendations are based 
on a deﬁ  nition of COPD as “a disease state characterised by 
airﬂ  ow limitation that is not fully reversible. The airﬂ  ow 
limitation is usually both progressive and associated with 
an abnormal inﬂ  ammatory reaction of the lungs to noxious 
particles or gases”. The airﬂ  ow obstruction is distinguished 
from that of asthma by being permanent, progressively 
increasing, with no, or very little, variability. 
Severity grade is determined by the level of airﬂ  ow 
limitation after bronchodilator test demonstrating no, or 
incomplete (<15%), reversibility. The principles of case 
management are the following: 
Table 3 Frequency of various conditions for which patients consulted health services in various countries implementing the Practical 
Approach to Lung Health 
    Respiratory  conditions          
  All   ARI      COPD     Asthma     Other*     Other   
Country  No.  % No.  % No.  %  No.    %  No.  %  No.  %
Bolivia  4,911 100.0%  1,045  21.3% 59  1.2%  11  0.2% 39  0.8% 3,757 76.5%
Kyrgystan  2,772 100.0%  859  31.0% 76  2.7%  26  0.9% 31  1.1% 1,780 64.2%
Morocco  15,911  100.0%  2,876  18.1% 20  0.1%  188  1.2% 268  1.7% 12,559  78.9%
Tunisia  4,747 100.0%  1,301  27.4% 27  0.6%  64  1.3% 83  1.7% 3,272 68.9%
Note: * includes tuberculosis cases: 5 from Bolivia, 1 from Kyrgystan, 6 from Morocco, and 1 from Tunisia.
Abbreviations:  ARI, ; COPD, chronic obstructive pulmonary disease. International Journal of COPD 2007:2(2)  145
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1.  Diagnosis of air ﬂ  ow obstruction based on spirometry: 
FEV/ FVC  <70%;
2.  Severity grade based on level of FEV1: 
 •    Stage 0: At risk – Normal spirometry; chronic symp-
toms (cough and sputum production).
 •    Stage I: Mild COPD – FEV1/FVC < 70%, FEV1   80% 
predicted and usually but not always chronic symptoms 
(cough, sputum production).  
 •    Stage II: Moderate COPD – FEV1/FVC < 70%, 50%   
FEV1 < 80% predicted and chronic symptoms (cough, 
sputum production) usually with shortness of breath.  
 •    Stage III:  Severe COPD – FEV1/FVC < 70%, 30%   
FEV1 < 50% predicted and chronic symptoms (cough, 
sputum production, dyspnoea)
 •    Stage IV : Very severe COPD – FEV1/FVC < 70%, FEV1 
< 30% or FEV1 < 50% predicted plus chronic respiratory 
failure with clinical signs of right heart failure;  
3.  Secondary prevention is based on:
 a.  smoking  cessation 
  b.   avoidance of other exacerbating factors (indoor, work 
place pollution) and 
   c.  inﬂ  uenza vaccination;
4.  Stepwise treatment based on inhaled bronchodilators 
(short-acting beta 2 and/or anticholinergics) and long-
acting beta agonists and inhaled steroids for moderate 
and severe cases with repeated exacerbations;
5. Rehabilitation; 
6.  Long term oxygen therapy for hypoxemia or heart 
failure. 
Efﬁ  cacy of interventions
Cochrane systematic reviews have conﬁ  rmed both efﬁ  cacy 
and safety of inhaled steroids in the management of asthma 
for adults and children (Adams et al 2001, 2005a, 2005b). All 
inhaled steroids demonstrate a dose-response relationship for 
efﬁ  cacy, but most of the beneﬁ  t is in mild to moderate disease 
with low-moderate dose range of each drug. In patients with 
severe disease who are dependant of oral steroids, there may 
be a beneﬁ  t in reducing oral steroids by using high-dose of 
inhaled steroids (Adams and Jones 2006). Long-acting beta 
agonists provide additional improvement in lung function 
and in symptoms and could reduce the rate of exacerbations 
requiring oral steroids without additional serious adverse 
reactions (Ni Chroinin et al 2004, 2005). 
Cochrane reviews of treatment of COPD have also been 
reported. Regular long-term use of ipratropium bromide, 
short-acting beta 2 agonist therapy or their combination show 
little beneﬁ  t in stable COPD in improving lung function, 
symptoms, or exercise tolerance. Patients can choose the 
short-acting bronchodilator that gives the most improvement 
of their symptoms (Appleton et al 2006). Long-acting beta 
agonists give small increases of FEV1 not associated with 
improvement in quality of life or reduction in breathlessness 
(Appleton et al 2001). Long-acting anticholinergics reduce 
COPD exacerbations and hospitalizations. 
Evaluation of effectiveness
The effectiveness of asthma guidelines has been demon-
strated in several studies, in particular the Gaining Optimal 
Asthma Control (GOAL) study (Bateman et al 2004). The 
cost-effectiveness of inhaled steroids in management of per-
sistent asthma has been consistently demonstrated, even in 
developing countries (Perera 1995). The number of hospital 
days and emergency visits can be reduced by 50% to 80% 
for asthma patients requiring inhaled steroids. Substantial 
savings in healthcare costs have also been demonstrated 
(Price and Briggs 2002; Castro et al 2003; Adams et al 2001 
Schelledy et al 2005: Simonella et al 2006).
Standard case management of COPD has been shown to 
improve the quality of life of patients and to decrease exac-
erbations and hospitalisations (Paggiaro et al 1998; Friedman 
et al 1999; Calverley et al 2003a, 2003b; Oostenbrink.et al 
2004), although long-term studies are lacking (Barr et al 
2005). Use of bronchodilators, steroids, and rehabilitation are 
recognized to be cost-effective (Rea et al 2004; Halpin 2006) 
in industrialized countries. Management of COPD using 
the combination of all technical measures is usually costly 
(Wouters 2003; Oostenbrink and Rutten-van Molken 2004; 
Fournier et al 2005) and is not able to arrest, or decrease the 
progression in, the decline of lung function. A meta-analysis 
systematically conducted reviewed the efﬁ  cacy, effective-
ness, and safety on inhaled steroids in patient with COPD, 
and concluded that the risk-beneﬁ  t ratio appears to favor 
inhaled steroids in patients with moderate to severe COPD 
(Gartlehner et al 2006), and  has estimated that unplanned 
use of health services can be reduced by one-third. However, 
existing evidence does not indicate a treatment beneﬁ  t for 
patients with mild COPD. 
Relevance for developing countries
Most developing countries have no standard guidelines for as-
sessing and managing chronic noncommunicable respiratory 
disease. Such services as exist in many low-income countries 
do not reach large parts of the population, particularly the 
poorest. A substantial proportion of this group of the popu-
lation dies before age 40 (before they have the ‘possibility’ International Journal of COPD 2007:2(2)  146
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of developing chronic airﬂ  ow limitation) and have limited 
or no access to health services. They represent 15% of the 
population in Latin America, 34% in the Middle East, and 
more than 40% in South-East Asia and Sub-Saharan Africa 
(UNDP 1997). A clear priority must be to enhance access 
to health services in general if these patients are to beneﬁ  t 
by the care they require.
Some guidelines have been published for the management 
of COPD in developing countries. They include early recogni-
tion of disease by questionnaire, conﬁ  rmation of diagnosis, 
and assessment of disease severity by clinical evaluation 
and spirometry (SAPS 1998; MHM and AMMMTS 1999). 
A standard case management approach for COPD for Asia 
and Africa has been proposed (Chan-Yeung et al 2004). The 
long term management recommended is a step-wise approach 
according to the disease severity (Figure 1) using only inex-
pensive bronchodilatators: inhaled beta 2 short-action and/or 
inhaled ipratropium bromide with or without low dosage 
of slow release theophylline. Inhaled steroids are reserved 
for those where a clear response to a standardized trial of 
steroids has been demonstrated. Long-term oxygen therapy 
and rehabilitation programmes are usually not available in 
low-income countries.
Although the publication and distribution of inter-
national consensus reports are important advances, the 
beneﬁ  ts have not yet reached patients in many developing 
countries. Results achieved are not the same as in clinical 
trials, even in industrialized countries (Rabe et al 2000, 
2004; Lai et al 2003; Neffen et al 2005). Such guidelines 
are usually developed by professional societies and/or 
specialists and rarely involve service providers at the 
primary care level (Lalloo and Mclvor 2006). Additional 
bottlenecks in developing countries are: the low priority 
accorded to chronic diseases as compared with infec-
tious diseases; lack of organization of follow-up; cultural 
barriers; poor education of health workers; lack of spirom-
etry in low-income countries; and lack of access to, and 
the high cost of necessary drugs (Sterk et al 1999; Enarson 
and Aït-Khaled 1999; Aït-Khaled et al 2000; Gelders et al 
2006; Wan and Aït-Khaled 2006).
The Union Asthma guide published in 1996 and 
revised in 2005 (Aït-Khaled and Enarson 2005) proposes 
a technical package for asthma management, implemented 
within general health services, and appropriate for services 
where resources are extremely limited. The standard case 
management approach recommends the use of two drugs, 
both of which are included in the WHO essential drugs list: 
inhaled beclomethasone 250 μg/puff and inhaled salbutamol 
100 μg/puff (Figure 2). A standardized information system 
is recommended, including a patient register in which each 
new patient with persistent asthma is registered, with infor-
mation on initial status and follow-up. Routine analysis of 
case notiﬁ  cation and of outcome of management is based 
on the register. Evaluation of this approach in several low- 
and middle-income countries demonstrated its feasibility 
(Aït-Khaled et al 2006a) and its efﬁ  ciency estimated after 
Inhaled salbutamol 100 μg as needed (2-4 puffs 
no more than 12 puffs)
Inhaled ipratropium bromide
2-6 puffs every 6 hours /day and
Inhaled salbutamol 100 μg 
as needed (2-4 puffsno more than 12 puffs)
Inhaled ipratropium bromide
2-6 puffs every 6 hours /day and  
Inhaled salbutamol 100 μg 
2-4 puffs 4 times  daily and *
Step 1
Step 2
Step 3
Step up
Figure 1 Step-wise approach to treatment for COPD in developing countries.
Note: * Add theophylline low dosage in noncontrolled patients and inhaled steroids if positive response to corticosteroid trial.International Journal of COPD 2007:2(2)  147
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one year of follow-up (Aït-Khaled et al 2006b). Despite 
a high proportion of patients (31%) who did not continue 
treatment for at least one year, 51% of patients in the cohort 
had a decrease in their severity of disease (Aït-Khaled 
et al 2006b); emergency visits and hospitalizations were 
dramatically reduced with substantial cost-saving to the 
health services. 
Setting priorities for management 
of chronic airﬂ  ow limitation
In developing countries, the objective of chronic respiratory 
disease prevention and management is to decrease the burden 
of illness, prevent avoidable deaths, and increase the quality 
of life of patients. This is achieved by adaptation of inter-
national guidelines to the particular context of developing 
countries. Such efforts have as objectives to (Aït-Khaled et al 
2001, 2002; Bousquet et al 2003):
•   Reduce tobacco smoking in the whole population;
•   Encourage smoking cessation for patients who access 
services;
•   Improve quality of services by standard case manage-
ment;
•   Promote cost-effective approaches to treatment;
•   Enhance access to affordable essential medications;
•   Avoid ineffective and costly services.
The tobacco industry has increasingly targeted developing 
countries (Amos 1996) and tobacco smoking has increased 
dramatically in many developing countries during the last 
two decades. The World Bank estimates that a 10% increase 
in economic level in middle income countries brings about 
an increase in tobacco consumption of 7%, whereas the 
same increase in the poorest countries leads to an increase 
in tobacco consumption of 13% (Yach 1996).
This problem requires ﬁ  rm political action directed to 
endorsing and implementing the Framework Convention 
on Tobacco Control and, particularly, to increase legislation 
to reduce tobacco consumption (WHO 1999). Secondary 
prevention is essential. This includes smoking cessation 
programmes, the simplest and most appropriate of which is 
an intervention called ‘brief advice’ (Slama et al 1995; Slama 
1998; Fiore et al 2000). In many countries, efforts to reduce 
the effects of exposure to combustion products of biomass 
fuel are important (Baris and Ezzati 2004). For COPD, a 
number of interventions are not justiﬁ  able and should not 
be used, including periodic courses of antibiotics, long-term 
oral steroids, and mucolytics.
For asthma, a Cochrane review concluded that there 
is insufﬁ  cient evidence to support initiating therapy with 
a combination of inhaled glucocorticoids and long-acting 
beta2-agonist rather than inhaled glucocorticoids alone as 
ﬁ  rst line therapy for persistent asthma in steroid-naïve adults 
(Ni Chroinin et al 2004). Costly investigations not recom-
mended for use in developing countries include allergy skin 
tests, measurement of total and speciﬁ  c IGE, and nonspeciﬁ  c 
bronchial challenge. Immunotherapy is not recommended in 
low income countries (Sterk et al 1999; Bousquet et al 2001) 
because, in addition to its very high cost and limited indica-
tions, many allergens are not well identiﬁ  ed in these developing 
countries, and rare side effects might be severe.
International guidelines for management of COPD may 
be very difﬁ  cult to implement in low-income countries as 
they require redirecting existing resources from other priority 
Inhaled beclomethasone 500 μg/day*
Inhaled beclomethasone*
1000 μg/day
Inhaled beclomethasone* 
2000 μg/day
Prednisolone ?
Intermittent
Mild
persistent
Moderate
persistent
Severe
persistent Step
down / up
Figure 2 Step-wise approach to treatment:The Union Asthma Guide.
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activities. This may be possible in some middle-income 
countries where the resources are greater and quality of 
services better and in some particular settings in low income 
countries (private hospitals or universities).
As resources are not limitless, it remains for governments 
to choose some interventions over others. To make these 
choices, a set of criteria has been proposed by the WHO, in 
collaboration with the Public Health Agency of Canada. In 
acknowledging the growing problem of chronic diseases 
in developing countries and its relative neglect, they have 
recommended the following deﬁ  nition of categories of cost-
effectiveness (WHO 2005):
•   Very cost-effective: interventions that avert each DALY 
at a cost less than gross domestic product per head;
•   Cost-effective: interventions that avert each DALY at a 
cost between one and three times gross domestic product 
per head;
•   Not cost-effective: interventions that avert each DALY 
at a cost higher than three times gross domestic product 
per head. 
Clearly, it is vital that researchers present the results of their 
investigations in these terms if decision-makers are to make 
use of them.
International responses
WHO has responded to the needs in two ways. A comprehen-
sive integrated package for the standardized management for 
respiratory disease, Practical Approach to Lung health (PAL) 
(Ottmani et al 2005), has been developed and implemented 
in several developing countries. More recently a new WHO 
initiative, Global Alliance for Respiratory Chronic Diseases 
(GARD), has been launched. The Union contributes to these 
initiatives through:
•   Creation of an Asthma Drug Facility to improve availabil-
ity and affordability of essential asthma drugs (Aït-Khaled 
2006; Billo 2004, 2006) 
•   Implementation of an integrated package for improvement 
of quality of care at the ﬁ  rst level of referral in developing 
countries. (Enarson 1998) 
Developing countries have been left behind while our 
understandings of respiratory disease, and the interven-
tions to deal with it, have improved in the past decade. 
The key obstacle to further action is the lack of compre-
hensive information on the burden of disease and the 
effects in intervention in relation to return on investment, 
the limited access to health services among the poor, and 
the insufficient adaptation and testing of standard case 
management. These key issues need to be addressed if we 
are to facilitate the care of more than one hundred million 
who suffer from chronic airflow limitation.
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